SEC Filing Summary: Synaptogenix, Inc. (SNPX)
Business Context and Reporting Period
This Form 8-K Current Report was filed by Synaptogenix, Inc. on April 14, 2023. The filing reports on a Special Meeting of stockholders held on the same date. The company is an emerging growth company incorporated in Delaware, with its principal executive offices in New York, New York.
Key Financial Metrics
The filing text does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on corporate governance and voting results.
Material Changes and Voting Results
At the Special Meeting, a quorum was established with 2,923,975 shares represented, constituting approximately 40.23% of outstanding common stock. Stockholders voted on a single proposal to authorize the issuance of common stock underlying convertible preferred stock and warrants issued under a November 17, 2022 Securities Purchase Agreement. This authorization is required to comply with Nasdaq Listing Rule 5635(d) for issuances exceeding 20% of pre-issuance outstanding shares.
- Proposal: Authorization of Issuance of Common Stock.
- Votes For: 2,077,004
- Votes Against: 791,292
- Abstentions: 55,679
The proposal was approved by the stockholders.
Guidance, Outlook, and Risks
The filing does not contain management commentary on future guidance, outlook, or specific risk factors beyond the context of the Nasdaq listing compliance. The primary contingency addressed is the regulatory requirement to obtain shareholder approval for significant equity issuances under the terms of the 2022 financing agreement.
Key Facts for Investor Verification
- Verify the total number of shares authorized for issuance under the November 17, 2022 Securities Purchase Agreement to assess potential dilution.
- Confirm the current outstanding share count to calculate the precise impact of the 20% threshold mentioned in the proposal.
- Review the Definitive Proxy Statement on Schedule 14A (filed March 27, 2023) for detailed terms of the convertible preferred stock and warrants.
- Monitor subsequent filings for the actual issuance of shares resulting from this authorization.